Statin Treatment Alters Serum N-3 to N-6 Polyunsaturated Fatty Acids Ratio in Patients with Dyslipidemia

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2015 Jul 8

PMID 26149129

Citations 18

Authors

Tsuyoshi Nozue

Ichiro Michishita

Affiliations

Soon will be listed here.

Abstract

Background: The effects of statins on serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) levels have not been fully evaluated. We examined the effects of two types of statins (rosuvastatin and pitavastatin) on serum PUFAs levels and their ratios in patients with dyslipidemia.

Findings: A total of 46 patients who were not receiving lipid-lowering therapy were randomly assigned to receive either 2.5 mg/day of rosuvastatin or 2 mg/day of pitavastatin. Serum PUFAs levels were measured at baseline, at 4 weeks, and at 12 weeks. Rosuvastatin was used to treat 23 patients, and the remaining 23 patients were treated using pitavastatin. Serum docosahexaenoic acid (DHA) levels decreased significantly at 12 weeks in both groups (rosuvastatin: from 169.6 to 136.3 μg/mL, p = 0.006; pitavastatin: from 188.6 to 153.9 μg/mL, p = 0.03). However, serum levels of eicosapentaenoic acid (EPA) and arachidonic acid (AA) did not change. In addition, the EPA/AA ratio did not change, whereas the DHA/AA ratio decreased significantly at 12 weeks in both groups (rosuvastatin: from 0.99 to 0.80, p = 0.01; pitavastatin: from 1.14 to 0.91, p = 0.003). No adverse events were observed during the study period.

Conclusions: In this small, open-label, pilot study, rosuvastatin and pitavastatin decreased serum DHA levels and the DHA/AA ratio in patients with dyslipidemia.

Citing Articles

Crucial Interactions between Altered Plasma Trace Elements and Fatty Acids Unbalance Ratio to Management of Systemic Arterial Hypertension in Diabetic Patients: Focus on Endothelial Dysfunction.

Gouaref I, Otmane A, Makrelouf M, Abderrhmane S, Haddam A, Koceir E Int J Mol Sci. 2024; 25(17).

PMID: 39273236 PMC: 11395650. DOI: 10.3390/ijms25179288.

X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction.

Zhang P, Munier J, Wiese C, Vergnes L, Link J, Abbasi F Nat Commun. 2024; 15(1):5571.

PMID: 38956041 PMC: 11219728. DOI: 10.1038/s41467-024-49764-2.

One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial.

Hoshi R, Alotaibi M, Liu Y, Watrous J, Ridker P, Glynn R Arterioscler Thromb Vasc Biol. 2024; 44(7):e196-e206.

PMID: 38841856 PMC: 11209760. DOI: 10.1161/ATVBAHA.124.321058.

Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial.

Kim M, Kim S, Lee S, An W J Yeungnam Med Sci. 2024; 41(3):188-195.

PMID: 38715530 PMC: 11294791. DOI: 10.12701/jyms.2024.00094.

Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers.

Kim J, Sunwoo J, Song J, Seo Y, Jung W, Nam K Pharmaceuticals (Basel). 2022; 15(8).

PMID: 36015110 PMC: 9415283. DOI: 10.3390/ph15080962.

References

Das U . Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids. 2001; 65(1):37-40. DOI: 10.1054/plef.2001.0285. View

Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-504. DOI: 10.1056/NEJMoa040583. View

Igel M, Sudhop T, von Bergmann K . Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol. 2002; 42(8):835-45. DOI: 10.1177/009127002401102731. View

Das U . Regarding the article: Hepatic ischemia/reperfusion injury is diminished by atorvastatin in Wistar rats. Arch Med Res. 2014; 45(5):439-40. DOI: 10.1016/j.arcmed.2014.06.002. View

Harris J, Hibbeln J, Mackey R, Muldoon M . Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids. 2004; 71(4):263-9. DOI: 10.1016/j.plefa.2004.06.001. View

FIELD F, Albright E, Mathur S . Effect of dietary n-3 fatty acids on HMG-CoA reductase and ACAT activities in liver and intestine of the rabbit. J Lipid Res. 1987; 28(1):50-8. View

Nakamura N, Hamazaki T, Ohta M, Okuda K, Urakaze M, Sawazaki S . Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res. 1999; 29(1):22-5. DOI: 10.1007/s005990050057. View

LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

Jula A, Marniemi J, Ronnemaa T, Virtanen A, Huupponen R . Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2005; 25(9):1952-9. DOI: 10.1161/01.ATV.0000177812.84927.fa. View

10.

Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y . Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369(9567):1090-8. DOI: 10.1016/S0140-6736(07)60527-3. View

11.

Hayashi T, Yokote K, Saito Y, Iguchi A . Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007; 8(14):2315-27. DOI: 10.1517/14656566.8.14.2315. View

12.

Shimano H, Arai H, Harada-Shiba M, Ueshima H, Ohta T, Yamashita S . Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb. 2008; 15(3):116-21. DOI: 10.5551/jat.e560. View

13.

Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y . Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008; 200(1):135-40. DOI: 10.1016/j.atherosclerosis.2008.06.003. View

14.

Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S . Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009; 73(7):1283-90. DOI: 10.1253/circj.cj-08-1197. View

15.

Ridker P, Genest J, Boekholdt S, Libby P, Gotto A, Nordestgaard B . HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010; 376(9738):333-9. DOI: 10.1016/S0140-6736(10)60713-1. View

16.

Das U . Beneficial actions of statins in the reduction of atrial fibrillation and stabilization and regression of coronary plaques: but how and why?. Circ J. 2010; 75(1):224-5. DOI: 10.1253/circj.cj-10-0939. View

17.

Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y . Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol. 2012; 111(1):6-11. DOI: 10.1016/j.amjcard.2012.08.038. View

18.

Kurisu S, Ishibashi K, Kato Y, Mitsuba N, Dohi Y, Nishioka K . Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels. 2011; 28(1):34-8. DOI: 10.1007/s00380-011-0213-6. View

19.

Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y . Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2013; 18(4):320-6. DOI: 10.1177/1074248412473202. View

20.

Das U . Statins and the prevention of dementia. CMAJ. 2001; 165(7):908-9. PMC: 81500. View